Pulmonary Embolism- Diagnosis by Dr.Tinku Joseph

Dr.Tinku Joseph
Dr.Tinku JosephDoctor - Interventional Pulmonologist
PULMONARY EMBOLISM
DIAGNOSIS
Dr.Tinku Joseph
DM Resident
Dept. Of Pulmonary Medicine
AIMS, Kochi.
Diagnostic Tests
 Imaging Studies
– CXR
– V/Q Scans
– Spiral Chest CT
– Pulmonary Angiography
– Echocardiograpy
 Laboratory Analysis
– CBC, ESR,
– D-Dimer
– ABG’s
 Ancillary Testing
– ECG
– Pulse Oximetry
D-dimer Test
 Fibrin split product
 Circulating half-life of 4-6 hours
 Quantitative test have 80-85% sensitivity, and 93-100%
negative predictive value
• False Positives:
Pregnant Patients Post-partum < 1 week
Malignancy Surgery within 1 week
Advanced age > 80 years Sepsis
Hemmorrhage CVA
Collagen Vascular Diseases
Hepatic Impairment
Arch Intern Med 2004;140:589
Diagnostic Testing
• D-dimer
– Qualitative
• Bed side RBC agglutination test
– “SimpliRED D-dimer”
– Quantitative
• Enzyme linked immunosorbent asssay
“Dimertest”
• Positive assay is > 500ng/ml
• VIDAS D-dimer, 2nd generation ELISA
test
D-DIMER
• False Positive D-Dimer
– Pregnancy
– Trauma
– Postoperative Recovery
– Inflammation
– Cancer
– Rheumatoid Factor
– Older Age
• False Negative D-Dimer
– Heparin
Pulmonary Embolism- Diagnosis  by Dr.Tinku Joseph
Prognostic Value of Troponins in Acute
Pulmonary Embolism
 Conclusion: Elevated troponin levels were associated
with a high risk of (early) death resulting from
pulmonary embolism (OR, 9.44; 95% CI, 4.14 to
21.49)
 These findings identify troponin as a promising tool
for rapid risk stratification of patients with
pulmonary embolism.
BNP & pro-BNP
 Typically greater in patients with PE.
 Sensitivity of 60% and specificity of 62%.
 At a threshold of 500 pg/mL, the sensitivity of pro-
BNP for predicting adverse events was 95%, and the
specificity was 57%.
Kucher N et al. Low pro-brain natriuretic peptide levels predict benign clinical
outcome in acute pulmonary embolism. Circulation 2003 Apr 1; 107:1576-8.
WBC
 Poor sensitivity and nonspecific
Can be as high as 20,000 in some patients
Hb
 PTE does not alter count but if extreme, consider
polycythemia, a known risk factor
ESR
 Don’t get one, terrible test in regard to any predictive
value
Doppler ultrasound of leg veins
Principle - Veins are normally compressible;
Presence of DVT renders veins non-compressible
50% of patients with PE have positive ultrasound
(95% of PE are due to leg DVT)
ECG
– 2 Most Common finding on ECG:
 Nonspecific ST-segment and T-wave changes
 Sinus Tachycardia
– Historical abnormality suggestive of PE
 S1Q3T3
 Right ventricular strain
 New incomplete RBBB
Echocardiography
 This modality generally has
limited accuracy in the
diagnosis.
 The overall sensitivity and
specificity for diagnosis of
central and peripheral
pulmonary embolism by ECHO is
59% and 77%.
 It may allow diagnosis of other
conditions that may be confused
with pulmonary embolism.
ECHO signs of PE
 RV enlargement or hypokinesis especially free wall
hypokinesis, with sparing of the apex (the McConnell
sign)
 60/60 Sign- Acceleration time of RV ejection <60ms
in the presence of TR pressure gradient </=
60mmHg.
 Interventricular septal flattening and paradoxical
motion toward the LV resulting in a “D-shaped” LV in
cross section.
 Tricuspid regurgitation
Echocardiography
Am J Med 122:257,2009
Echocardiogram in PE
ABG analysis
 ABG has a limited role.
 It usually reveal hypoxemia,
hypocapnia and respiratory
alkalosis.
 Alveolar arterial oxygen gradient
, done at room air, a-a gradient >
15-20 is considered abnormal.
Chest x ray
 A normal or nearly
normal chest x-ray
Chest Xray
 Chest radiograph findings in patient with pulmonary
embolism
Result Percent
Cardiomegaly 27%
Normal study 24%
Atelectasis 23%
Elevated Hemidiaphragm 20%
Pulmonary Artery Enlargement 19%
Pleural Effusion 18%
Parenchymal Pulmonary Infiltrate 17%
Am Heart J 1997;134:479-87
Radiographic signs of acute pulmonary
embolism
 Signs with relative high specificity but low
sensitivity for acute pulmonary embolism:
 Decreased vascularity in the peripheral lung (Westermark sign).
 Enlargement of the central pulmonary artery (Fleischner sign).
 Enlarged right descending pulmonary artery (Palla's sign)
 Pleural based areas of increased opacity (Hampton hump).
 Hemidiaphragm elevation.
 Non specific signs associated with acute pulmonary
embolism that may be associated with other diseases:
 Focal area of increased opacity.
 Linear atelectasis.
 Pleural effusion.
Radiographic signs of acute pulmonary
embolism
Westermark’s sign
Westermark sign, with hilar enlargement
Dilatation of
pulmonary vessels
proximal to
embolism along
with collapse of
distal vessels, often
with a sharp cut off.
Pulmonary Embolism- Diagnosis  by Dr.Tinku Joseph
Hampton’s hump
Hampton’s hump
 Dome shaped pleural based opacity due to lung
infarction.
 Pulmonary infarct is dome shaped instead of being
wedge shaped because of double blood supply with
preserved bronchial arteries resulting in sparing of the
expected apex of the wedge.
Radiographic Eponyms
- Hampton’s Hump, Westermark’s Sign
Westermark’s
Sign
Hampton’s Hump
Ventilation/Perfusion Scan
- “V/Q Scan”
 A common modality to image the
lung.
 Relatively noninvasive.
 In many centers remains the initial
test of choice
 Preferred test in pregnant patients
 50 mrem vs 800mrem (with spiral CT)
V/Q Scan
VQ scan
Technique
Normal
Ventilation
Left UL PE
Perfusion scanVentillation scan
Ventilation/Perfusion Scan
 HIGH PROBABILITY (>80%): 2 or more large mismatched
segments or the equivalent.
 any perfusion defect substantially larger than
radiographic abnormality
 INTERMEDIATE PROBABILITY (20-79%): 1 moderate to 2
large mismatched segments
 LOW PROBABILITY (<20%): Non-segmental perfusion
defects, matched defects
 NORMAL: no perfusion defects
PIOPED: PREDICTIVE VALUE V/Q SCAN
SCAN CATEGORY CLINICAL SUSPICION
80-100% 20-79% 0-19%
HIGH
INTERMEDIATE
LOW
PIOPED INVESTIGATORS.
JAMA.1990; 263: 2753-2759
VQ Scan
Spiral CT
 Major advantage of Spiral CT is speed:
 Often the patient can hold their breath for
the entire study, reducing motion artifacts.
 Allows for more optimal use of intravenous
contrast enhancement.
 Spiral CT is quicker than the equivalent
conventional CT permitting the use of higher
resolution acquisitions in the same study
time.
 Contraindicated in cases of renal disease.
 Sensitive for PE in the proximal pulmonary
arteries, but less so in the distal segments.
CT Angiogram
 Quickly becoming the test of choice for initial
evaluation of a suspected PE.
 CT unlikely to miss any lesion.
 Better sensitivity, specificity and can be used directly
to screen for PE.
 Used to follow up “non diagnostic V/Q scans.
CT Angiogram
Chest computed tomography scanning
demonstrating extensive embolization of
the pulmonary arteries.
Multidetector Helical CT Pulmonary Angiography
Multidetector Helical CT Pulmonary Angiography
Advantages
Multidetector Helical CT Pulmonary Angiography
Limitations
CT findings of acute pulmonary embolism
Vascular abnormalities:
 Intraluminal filling defects that forms an acute
angle with the vessel wall & may be surrounded by
contrast material (polo mint sign or railway sign).
 Total cutoff of vascular enhancement.
 Enlargement of the occluded vessel.
Ancillary findings:
 Pleural based wedge shaped areas of increased
attenuation with no contrast enhancement.
 Linear atelectasis.
Partial eccentric filling defect with acute
angle with the vessel wall
Intraluminal filling defect
(polo mint sign)
Intraluminal filling defect
(railway track sign)
Enlargment of the occluded vessel
Ancillary findings of acute pulmonary
embolism
(atelectatic band)
MRA
MRA
Pulmonary angiogram
 Gold Standard.
 Positive angiogram provides 100% certainty that an
obstruction exists in the pulmonary artery.
 Negative angiogram provides > 90% certainty in the
exclusion of PE.
 “Court of Last Resort”
Pulmonary angiogram
Left-sided pulmonary
angiogram showing extensive
filling defects within the left
pulmonary artery and its
branches.
Angiographic severity scoring
Miller, et al. Amer Journ Roent,Rad Therapy & Nuc Med. 125(4):895-9, 1975 Dec.
Further Alternative Imaging Tests (Newer modalities)
Dual-energy CTPA
Electrocardiographically gated CTPA
Three-dimensional images acquired by single-
photon emission computed tomography (SPECT)
using a gamma-emitting radioisotope may improve
V/Q scintigraphy and has a lower radiation dose.
Dual-energy CTPA
Provides functional and anatomic lung imaging
Demonstrates perfusion defects beyond obstructive and non-
obstructive clots
Diagnostic accuracy requires further research
Advantages
Indirect evaluation of peripheral pulmonary arterial bed
Disadvantages
Longer data acquisition time
Increased radiation exposure
Dual-energy CTPA
[A] Axial reconstruction with color-coded
dual energy perfusion information. Note
the large perfusion defects in both lungs.
[B] Coronal reconstruction. Only
the apical parts show a normal
perfusion.
Electrocardiographically gated
CTPA
Can differentiate between cardiac events and PE
 May be of use in patients presenting with thoracic pain and
suspected PE, cardiac events, or aorta dissection.
 More contrast material is needed, and the radiation dose is
higher compared with CTPA.
Imaging in Pregnancy
 No validated clinical decision rules
 No consensus in evidence for diagnostic imaging algorithm
 Balance risk of radiation vs. risk of missed fatal diagnosis or
unnecessary anticoagulation
 MDCT delivers higher radiation dose to mother but lower
dose to fetus than V/Q scanning
 Consider low-dose CT-PA or reduced-dose lung scintigraphy
Stein P et al. Radiology. 2007 Jan;242:15-21.
Marik PE; Plante LA. N. Engl. J. Med. 2008;359:2025-33.
Imaging-nut shell
 Plain chest radiograph – Usually normal and non-
specific signs.
 Radionuclide ventilation-perfusion lung scan –
Excellent negative predictive value.
 CT Angiography of the pulmonary arteries – Quickly
becoming method of choice.
 Pulmonary angiography – Gold standard but invasive.
Diagnostic Tests for Suspected Pulmonary
Embolism
Oxygen saturation Nonspecific, but suspect PE if there is a sudden, otherwise
unexplained decrement
D-dimer An excellent “rule-out” test if normal, especially if accompanied
by non–high clinical probability
Electrocardiography
May suggest an alternative diagnosis, such as myocardial
infarction or pericarditis
Lung scanning Usually provides ambiguous result; used in lieu of chest CT for
patients with anaphylaxis to contrast agent, renal insufficiency, or
pregnancy
Chest CT The most accurate diagnostic imaging test for PE ; beware if CT
result and clinical likelihood probability are discordant
Pulmonary angiography Invasive, costly, uncomfortable; used primarily when local
catheter intervention is planned
Echocardiography Best used as a prognostic test in patients with established PE
rather than as a diagnostic test ; many patients with large PE will
have normal echocardiograms
Venous ultrasonography Excellent for diagnosis of acute symptomatic proximal DVT; a
normal study does not rule out PE because a recent leg DVT may
have embolized completely; calf vein imaging is operator
dependent
Magnetic resonance Reliable only for imaging of proximal segmental pulmonary
arteries; requires gadolinium but does not require iodinated
contrast agent
Pulmonary Embolism- Diagnosis  by Dr.Tinku Joseph
Pulmonary Embolism- Diagnosis  by Dr.Tinku Joseph
Pulmonary Embolism
(Treatment) Part 2
Dr.Tinku Joseph
DM Resident
Dept. Of Pulmonary Medicine
AIMS, Kochi.
Approach to the patient of PE
 Stratify patients into high clinical likelihood or non–
high clinical likelihood of PE .
 In low-risk group, only about 5% of patients were
subsequently diagnosed with PE.
How do we work up?
- Pretest Probability
 Definition: “The probability of the target disorder
(PE) before a diagnostic test result is known”.
 Used to decide how to proceed with diagnostic
testing and final disposition
Classic Wells Criteria to Assess Clinical
Likelihood of Pulmonary Embolism
SCORE POINTS
DVT symptoms or signs 3
An alternative diagnosis is less
likely than PE
3
Heart rate >100/min 1.5
Immobilization or surgery
within 4 weeks
1.5
Prior DVT or PE 1.5
Hemoptysis 1
Cancer treated within 6 months
or metastatic
1
>4 score points = high probability
≤4 score points = non–high probability JAMA 295:172,2006
Simplified Wells Criteria to Assess Clinical Likelihood
of Pulmonary Embolism
DVT symptoms or signs 1
An alternative diagnosis is less
likely than PE
1
Heart rate >100/min 1
Immobilization or surgery
within 4 weeks
1
Prior DVT or PE 1
Hemoptysis 1
Cancer treated within 6 months
or metastatic
1
>1 score point = high probability
≤1 score point = non–high probability
Thromb Haemost 101:197,2009
Original Geneva score
Revised Geneva score
ACC/AHA Classification
• Massive
• Submassive
• Low-Risk PE
• Pulmonary infarction syndrome
Massive PE
• Acute PE with sustained hypotension (systolic blood
pressure 90 mm Hg for at least 15 minutes or
requiring inotropic support, not due to a cause other
than PE, such as
 Arrhythmia
 Hypovolemia
 Sepsis
 Left ventricular (LV) dysfunction
 Pulselessness
 Persistent profound bradycardia (heart rate 40 bpm
with signs or symptoms of shock)
Submassive PE
• Acute PE without systemic hypotension (systolic blood pressure 90mm Hg)
but with either RV dysfunction or myocardial necrosis
• RV dysfunction means the presence of at least 1 of the following
 RV dilation (apical 4-chamber RV diameter divided by LV diameter 0.9) or
RV systolic dysfunction on echocardiography
 RV dilation (4-chamber RV diameter divided by LV diameter 0.9) on CT
 Elevation of BNP (90 pg/mL)
 Elevation of N-terminal pro-BNP (500 pg/mL)
 Electrocardiographic changes (new complete or incomplete right bundle-
branch block, anteroseptal ST elevation or depression, or anteroseptal T-
wave inversion)
Torbicki A et al. Eur Heart J 29(18):2276–2315,
2008
Low-Risk PE
• Acute PE and the absence of the clinical
markers of adverse prognosis that define
massive or submassive PE
Pulmonary Infarction Syndrome
• Caused by a tiny peripheral pulmonary embolism
 Pleuritic chest pain, often not responsive to
narcotics
 Low-grade fever
 Leukocytosis
 Pleural rub
 Occasional scant hemoptysis
Treatment:
Goals:
 Prevent death from a current embolic event
 Reduce the likelihood of recurrent embolic events
 Minimize the long-term morbidity of the event
Treatment options
 Symptomatic treatment:
– ABCD approach
– Oxygen
– Analgesia
 Anticoagulation:
– IV Heparin
– S/C LMWH eg Enoxaparine, Dalteparine
– Oral Warfarin
 IVC filter: If there is contra-indications for anti-coagulation
 Thrombolysis: tPA eg Alteplase, Tenectaplase
 Surgical procedures: Pulmonary embolectomy
Treatment options
 Massive PE: Thrombolysis/embolectomy
 Sub-massive PE: Strongly consider
thrombolysis/embolectomy but need to balance risk
of bleeding
 Non-massive PE: Anticoagulation
KEY STUDIES & guidelines IN PE
TREATMENT
• 1937 Murry: first use of heparin
• 1960 Barritt:“RCT” warfarin vs.
placebo
• 1968 Sasahara: UPET
• 2003 Konstantinides: Alteplase
Pulmonary Embolism- Diagnosis  by Dr.Tinku Joseph
Prevention
 ACCP guide lines
• For acutely ill hospitalised medical pts at low risk of
thrombosis ACCP recommends against the use of
prophylaxsis.
• Pts at moderate to high risk but who are not
bleeding or at high risk of bleeding should be given
either LMWH or UFH or fondaparinux.
Padua Score
Prevention of PE
1 Hospitalization with
medical illness
Enoxaparin 40 mg SC qd or
Dalteparin 5000 units SC qd or
Fondaparinux 2.5 mg SC qd (in patients with a
heparin allergy such as heparin-induced
thrombocytopenia) or
Graduated compression stockings or intermittent
pneumatic compression
2 General surgery Unfractionated heparin 5000 units SC bid or tid or
Enoxaparin 40 mg SC qd or
Dalteparin 2500 or 5000 units SC qd
3 Major orthopedic
surgery
Warfarin (target INR 2 to 3) or
Enoxaparin 30 mg SC bid or
Enoxaparin 40 mg SC qd or
Dalteparin 2500 or 5000 units SC qd or
Fondaparinux 2.5 mg SC qd
Rivaroxaban 10 mg qd (in Canada and Europe)
Dabigatran 220 mg bid (in Canada and Europe)
4 Oncologic surgery Enoxaparin 40 mg SC qd
5 Neurosurgery Unfractionated heparin 5000 units SC bid or
Enoxaparin 40 mg SC qd and
Graduated compression stockings or intermittent
pneumatic compression
Consider surveillance lower extremity ultrasonography
6 Thoracic surgery Unfractionated heparin 5000 units SC tid and
Graduated compression stockings or intermittent
pneumatic compression
Prevention of PE
• For pts who are bleeding or at risk of bleeding use
leg compression devices only.
• Pts are considered to be at high risk of bleeding if
they meet any of the following criteria
• Active gastrodeodenal ulcer
• Bleeding in 3 months prior to admission
• Platelet count <50,000
Prevention of PE
 Or if they had multiple risk
factors for bleeding of lesser
predictive strengthlike age >84
yrs,severe renal failure , hepatic
failure with INR > 1.5 , male
,current cancer, ICU admission.
Prevention of PE
References
 Harrison -18 th edition
 ACCP guidelines
 Fishman's Pulmonary Diseases and Disorders
 Crofton and Douglas's Respiratory Diseases
(Wiley, 2000)
1 de 83

Recomendados

Pulmonary embolism - Diagnosis and management por
Pulmonary embolism - Diagnosis and managementPulmonary embolism - Diagnosis and management
Pulmonary embolism - Diagnosis and managementDr Vivek Baliga
3.3K vistas29 diapositivas
pulmonary embolism por
pulmonary embolismpulmonary embolism
pulmonary embolismaravazhi
9.8K vistas101 diapositivas
Pulmonary embolism ( PE) por
Pulmonary embolism ( PE)Pulmonary embolism ( PE)
Pulmonary embolism ( PE)Mohamed Elbhnasawy
2.1K vistas45 diapositivas
Pulmonary thromboembolism por
Pulmonary thromboembolismPulmonary thromboembolism
Pulmonary thromboembolismcamiij1
3K vistas34 diapositivas
Pulmonary embolism por
Pulmonary embolismPulmonary embolism
Pulmonary embolismFarrukh Masood
4.3K vistas23 diapositivas
Pulmonary embolism por
Pulmonary embolism Pulmonary embolism
Pulmonary embolism RahulGupta1687
6.2K vistas65 diapositivas

Más contenido relacionado

La actualidad más candente

Pulmonary hypertension (2014) dr.tinku joseph por
Pulmonary hypertension (2014) dr.tinku josephPulmonary hypertension (2014) dr.tinku joseph
Pulmonary hypertension (2014) dr.tinku josephDr.Tinku Joseph
50.4K vistas72 diapositivas
Pulmonary thromboembolism por
Pulmonary thromboembolismPulmonary thromboembolism
Pulmonary thromboembolismRikin Hasnani
17.1K vistas42 diapositivas
Constrictive pericarditis por
Constrictive pericarditisConstrictive pericarditis
Constrictive pericarditisWaqas Khalid
1.9K vistas50 diapositivas
Constrictive pericarditis por
Constrictive pericarditis Constrictive pericarditis
Constrictive pericarditis Ramachandra Barik
27.6K vistas33 diapositivas
Pulmonary embolism radiology imaging por
Pulmonary embolism radiology imagingPulmonary embolism radiology imaging
Pulmonary embolism radiology imagingharshvardhan
2.6K vistas69 diapositivas
HOCM Hypertrophic cardiomyopathy por
HOCM Hypertrophic cardiomyopathyHOCM Hypertrophic cardiomyopathy
HOCM Hypertrophic cardiomyopathyPlease hit like if you really liked my PPTs
11.6K vistas47 diapositivas

La actualidad más candente(20)

Pulmonary hypertension (2014) dr.tinku joseph por Dr.Tinku Joseph
Pulmonary hypertension (2014) dr.tinku josephPulmonary hypertension (2014) dr.tinku joseph
Pulmonary hypertension (2014) dr.tinku joseph
Dr.Tinku Joseph50.4K vistas
Pulmonary thromboembolism por Rikin Hasnani
Pulmonary thromboembolismPulmonary thromboembolism
Pulmonary thromboembolism
Rikin Hasnani17.1K vistas
Constrictive pericarditis por Waqas Khalid
Constrictive pericarditisConstrictive pericarditis
Constrictive pericarditis
Waqas Khalid1.9K vistas
Pulmonary embolism radiology imaging por harshvardhan
Pulmonary embolism radiology imagingPulmonary embolism radiology imaging
Pulmonary embolism radiology imaging
harshvardhan2.6K vistas
Pulmonary hypertension por Abhay Mange
Pulmonary hypertensionPulmonary hypertension
Pulmonary hypertension
Abhay Mange85.8K vistas
Pulmonary Oedema - Pathophysiology - Approach & Management por Arun Vasireddy
Pulmonary Oedema  - Pathophysiology - Approach & ManagementPulmonary Oedema  - Pathophysiology - Approach & Management
Pulmonary Oedema - Pathophysiology - Approach & Management
Arun Vasireddy45.7K vistas
Hypertrophic cardiomyopathy por Fuad Farooq
Hypertrophic cardiomyopathyHypertrophic cardiomyopathy
Hypertrophic cardiomyopathy
Fuad Farooq28.8K vistas
Aortic dissection nikku ppt por Nikhil Vaishnav
Aortic dissection nikku pptAortic dissection nikku ppt
Aortic dissection nikku ppt
Nikhil Vaishnav21.7K vistas
Pulmonary embolism radiology por Anish Choudhary
Pulmonary embolism radiologyPulmonary embolism radiology
Pulmonary embolism radiology
Anish Choudhary20.8K vistas
Aortic regurgitation por Silah Aysha
Aortic regurgitationAortic regurgitation
Aortic regurgitation
Silah Aysha5.2K vistas
Pulmonary embolism notes 2021 por Best Doctors
Pulmonary embolism notes 2021Pulmonary embolism notes 2021
Pulmonary embolism notes 2021
Best Doctors 427 vistas
Acute Pulmonary Embolism por Sariu Ali
Acute Pulmonary EmbolismAcute Pulmonary Embolism
Acute Pulmonary Embolism
Sariu Ali8.8K vistas
14 Valvular Heart Disease por ghalan
14 Valvular Heart Disease14 Valvular Heart Disease
14 Valvular Heart Disease
ghalan8.8K vistas
Xaheer shah...pulmonary embolism por zaheer shah
Xaheer shah...pulmonary embolismXaheer shah...pulmonary embolism
Xaheer shah...pulmonary embolism
zaheer shah2.5K vistas

Similar a Pulmonary Embolism- Diagnosis by Dr.Tinku Joseph

deep vein thrombosis and pe por
deep vein thrombosis and pedeep vein thrombosis and pe
deep vein thrombosis and pePraveen Shukla
865 vistas76 diapositivas
Imaging of Pulmonary Embolism por
Imaging of Pulmonary Embolism  Imaging of Pulmonary Embolism
Imaging of Pulmonary Embolism Gamal Agmy
29.9K vistas79 diapositivas
Pulmonaryembolism final por
Pulmonaryembolism finalPulmonaryembolism final
Pulmonaryembolism finalLPS Institute of Cardiology Kanpur UP India
10.7K vistas131 diapositivas
CTA OF PULMONARY EMBOLISM por
CTA OF PULMONARY EMBOLISMCTA OF PULMONARY EMBOLISM
CTA OF PULMONARY EMBOLISMXiu Srithammasit
27.5K vistas110 diapositivas
Pulmonary embolism por
Pulmonary embolismPulmonary embolism
Pulmonary embolismNaglaa Mahmoud
2.1K vistas60 diapositivas
Pulmonary angiography por
Pulmonary angiographyPulmonary angiography
Pulmonary angiographyPankaj Kaira
9.3K vistas60 diapositivas

Similar a Pulmonary Embolism- Diagnosis by Dr.Tinku Joseph(20)

deep vein thrombosis and pe por Praveen Shukla
deep vein thrombosis and pedeep vein thrombosis and pe
deep vein thrombosis and pe
Praveen Shukla865 vistas
Imaging of Pulmonary Embolism por Gamal Agmy
Imaging of Pulmonary Embolism  Imaging of Pulmonary Embolism
Imaging of Pulmonary Embolism
Gamal Agmy29.9K vistas
Pulmonary angiography por Pankaj Kaira
Pulmonary angiographyPulmonary angiography
Pulmonary angiography
Pankaj Kaira9.3K vistas
Pulmonary embolism@ghanem@.2013 por Islam Ghanem
Pulmonary embolism@ghanem@.2013Pulmonary embolism@ghanem@.2013
Pulmonary embolism@ghanem@.2013
Islam Ghanem4K vistas
VQ scan of lung por airwave12
VQ scan of lungVQ scan of lung
VQ scan of lung
airwave1216.4K vistas
Pulmonary embolism,overview por Eman Mahmoud
Pulmonary embolism,overviewPulmonary embolism,overview
Pulmonary embolism,overview
Eman Mahmoud7.1K vistas
Pulmonary Embolism por cairo1957
Pulmonary EmbolismPulmonary Embolism
Pulmonary Embolism
cairo19576.2K vistas
Update on Pulmonary Embolism por Muhanad Majeed
Update on Pulmonary EmbolismUpdate on Pulmonary Embolism
Update on Pulmonary Embolism
Muhanad Majeed495 vistas
Updates in venous thromboembolism por Gamal Agmy
Updates in venous thromboembolismUpdates in venous thromboembolism
Updates in venous thromboembolism
Gamal Agmy3.9K vistas
Ultrasonography in Critically Ill Patients por Gamal Agmy
Ultrasonography in Critically Ill PatientsUltrasonography in Critically Ill Patients
Ultrasonography in Critically Ill Patients
Gamal Agmy2.1K vistas
VP pulmonary thmboembolism.pptx por vishwanath0908
VP pulmonary thmboembolism.pptxVP pulmonary thmboembolism.pptx
VP pulmonary thmboembolism.pptx
vishwanath0908149 vistas

Más de Dr.Tinku Joseph

Endobronchial Brachytherapy by Dr.Tinku Joseph por
Endobronchial Brachytherapy  by Dr.Tinku JosephEndobronchial Brachytherapy  by Dr.Tinku Joseph
Endobronchial Brachytherapy by Dr.Tinku JosephDr.Tinku Joseph
1.4K vistas36 diapositivas
HRCT Chest - By Dr. Tinku Joseph por
HRCT Chest - By Dr. Tinku JosephHRCT Chest - By Dr. Tinku Joseph
HRCT Chest - By Dr. Tinku JosephDr.Tinku Joseph
22K vistas153 diapositivas
Recent advances in Asthma & COPD by Dr.Tinku Joseph por
Recent advances in Asthma & COPD by  Dr.Tinku JosephRecent advances in Asthma & COPD by  Dr.Tinku Joseph
Recent advances in Asthma & COPD by Dr.Tinku JosephDr.Tinku Joseph
3.1K vistas55 diapositivas
Endobronchial Brachytherapy by Dr.Tinku Joseph por
Endobronchial Brachytherapy by  Dr.Tinku JosephEndobronchial Brachytherapy by  Dr.Tinku Joseph
Endobronchial Brachytherapy by Dr.Tinku JosephDr.Tinku Joseph
2.7K vistas36 diapositivas
VAP/HAP management guidelines by IDSA/ATS (2016) -: Dr.Tinku Joseph por
VAP/HAP management guidelines  by IDSA/ATS (2016) -: Dr.Tinku JosephVAP/HAP management guidelines  by IDSA/ATS (2016) -: Dr.Tinku Joseph
VAP/HAP management guidelines by IDSA/ATS (2016) -: Dr.Tinku JosephDr.Tinku Joseph
10.9K vistas52 diapositivas
Hepatopulmonary Syndrome By Dr.Tinku Joseph por
Hepatopulmonary Syndrome By Dr.Tinku JosephHepatopulmonary Syndrome By Dr.Tinku Joseph
Hepatopulmonary Syndrome By Dr.Tinku JosephDr.Tinku Joseph
11.5K vistas61 diapositivas

Más de Dr.Tinku Joseph(20)

Endobronchial Brachytherapy by Dr.Tinku Joseph por Dr.Tinku Joseph
Endobronchial Brachytherapy  by Dr.Tinku JosephEndobronchial Brachytherapy  by Dr.Tinku Joseph
Endobronchial Brachytherapy by Dr.Tinku Joseph
Dr.Tinku Joseph1.4K vistas
HRCT Chest - By Dr. Tinku Joseph por Dr.Tinku Joseph
HRCT Chest - By Dr. Tinku JosephHRCT Chest - By Dr. Tinku Joseph
HRCT Chest - By Dr. Tinku Joseph
Dr.Tinku Joseph22K vistas
Recent advances in Asthma & COPD by Dr.Tinku Joseph por Dr.Tinku Joseph
Recent advances in Asthma & COPD by  Dr.Tinku JosephRecent advances in Asthma & COPD by  Dr.Tinku Joseph
Recent advances in Asthma & COPD by Dr.Tinku Joseph
Dr.Tinku Joseph3.1K vistas
Endobronchial Brachytherapy by Dr.Tinku Joseph por Dr.Tinku Joseph
Endobronchial Brachytherapy by  Dr.Tinku JosephEndobronchial Brachytherapy by  Dr.Tinku Joseph
Endobronchial Brachytherapy by Dr.Tinku Joseph
Dr.Tinku Joseph2.7K vistas
VAP/HAP management guidelines by IDSA/ATS (2016) -: Dr.Tinku Joseph por Dr.Tinku Joseph
VAP/HAP management guidelines  by IDSA/ATS (2016) -: Dr.Tinku JosephVAP/HAP management guidelines  by IDSA/ATS (2016) -: Dr.Tinku Joseph
VAP/HAP management guidelines by IDSA/ATS (2016) -: Dr.Tinku Joseph
Dr.Tinku Joseph10.9K vistas
Hepatopulmonary Syndrome By Dr.Tinku Joseph por Dr.Tinku Joseph
Hepatopulmonary Syndrome By Dr.Tinku JosephHepatopulmonary Syndrome By Dr.Tinku Joseph
Hepatopulmonary Syndrome By Dr.Tinku Joseph
Dr.Tinku Joseph11.5K vistas
Allergic Broncho Pulmonary Aspergillosis (ABPA) by Dr.Tinku Joseph por Dr.Tinku Joseph
Allergic Broncho Pulmonary Aspergillosis (ABPA) by Dr.Tinku JosephAllergic Broncho Pulmonary Aspergillosis (ABPA) by Dr.Tinku Joseph
Allergic Broncho Pulmonary Aspergillosis (ABPA) by Dr.Tinku Joseph
Dr.Tinku Joseph11.6K vistas
Arterial lines by Dr.Tinku Joseph por Dr.Tinku Joseph
Arterial lines by Dr.Tinku JosephArterial lines by Dr.Tinku Joseph
Arterial lines by Dr.Tinku Joseph
Dr.Tinku Joseph39.2K vistas
Delirium in ICU -By Dr.Tinku Joseph por Dr.Tinku Joseph
Delirium in ICU -By Dr.Tinku JosephDelirium in ICU -By Dr.Tinku Joseph
Delirium in ICU -By Dr.Tinku Joseph
Dr.Tinku Joseph5.5K vistas
ventilator Associated Pneumonia -By Dr.Tinku Joseph por Dr.Tinku Joseph
ventilator Associated Pneumonia -By Dr.Tinku Josephventilator Associated Pneumonia -By Dr.Tinku Joseph
ventilator Associated Pneumonia -By Dr.Tinku Joseph
Dr.Tinku Joseph36.9K vistas
ECMO part 2 by Dr.Tinku Joseph por Dr.Tinku Joseph
ECMO part 2 by Dr.Tinku JosephECMO part 2 by Dr.Tinku Joseph
ECMO part 2 by Dr.Tinku Joseph
Dr.Tinku Joseph5.8K vistas
ECMO - Part 1 by Dr.Tinku Joseph por Dr.Tinku Joseph
ECMO - Part 1 by Dr.Tinku JosephECMO - Part 1 by Dr.Tinku Joseph
ECMO - Part 1 by Dr.Tinku Joseph
Dr.Tinku Joseph10.5K vistas
Small Cell Lung Cancer Management by Dr.Tinku Joseph por Dr.Tinku Joseph
Small Cell Lung Cancer Management by Dr.Tinku JosephSmall Cell Lung Cancer Management by Dr.Tinku Joseph
Small Cell Lung Cancer Management by Dr.Tinku Joseph
Dr.Tinku Joseph5.5K vistas
Stem cell therapy and lungs - Dr.Tinku Joseph por Dr.Tinku Joseph
Stem cell therapy and lungs  - Dr.Tinku JosephStem cell therapy and lungs  - Dr.Tinku Joseph
Stem cell therapy and lungs - Dr.Tinku Joseph
Dr.Tinku Joseph6.2K vistas
Pleural Mesothelioma - Dr.Tinku Joseph por Dr.Tinku Joseph
Pleural Mesothelioma - Dr.Tinku JosephPleural Mesothelioma - Dr.Tinku Joseph
Pleural Mesothelioma - Dr.Tinku Joseph
Dr.Tinku Joseph13.2K vistas
Bronchial Artery Embolization- By Dr.Tinku Joseph por Dr.Tinku Joseph
Bronchial Artery Embolization- By Dr.Tinku JosephBronchial Artery Embolization- By Dr.Tinku Joseph
Bronchial Artery Embolization- By Dr.Tinku Joseph
Dr.Tinku Joseph24.7K vistas
Basic concepts in treatment of Pulmonary Tuberculosis - By Dr.Tinku Joseph por Dr.Tinku Joseph
Basic concepts in treatment of Pulmonary Tuberculosis - By Dr.Tinku JosephBasic concepts in treatment of Pulmonary Tuberculosis - By Dr.Tinku Joseph
Basic concepts in treatment of Pulmonary Tuberculosis - By Dr.Tinku Joseph
Dr.Tinku Joseph6.3K vistas
Respiratory system anatomy Dr.Tinku Joseph por Dr.Tinku Joseph
Respiratory system anatomy  Dr.Tinku JosephRespiratory system anatomy  Dr.Tinku Joseph
Respiratory system anatomy Dr.Tinku Joseph
Dr.Tinku Joseph16K vistas

Último

Cholera Romy W. (3).pptx por
Cholera Romy W. (3).pptxCholera Romy W. (3).pptx
Cholera Romy W. (3).pptxrweth613
53 vistas11 diapositivas
DEBATE IN CA BLADDER TMT VS CYSTECTOMY por
DEBATE IN CA BLADDER TMT VS CYSTECTOMYDEBATE IN CA BLADDER TMT VS CYSTECTOMY
DEBATE IN CA BLADDER TMT VS CYSTECTOMYKanhu Charan
48 vistas42 diapositivas
When HER2 Is Low or Negative: Emerging Evidence on Antibody-Drug Conjugates f... por
When HER2 Is Low or Negative: Emerging Evidence on Antibody-Drug Conjugates f...When HER2 Is Low or Negative: Emerging Evidence on Antibody-Drug Conjugates f...
When HER2 Is Low or Negative: Emerging Evidence on Antibody-Drug Conjugates f...PeerVoice
6 vistas35 diapositivas
Thrives Priority Areas: Behavioral Health por
Thrives Priority Areas: Behavioral HealthThrives Priority Areas: Behavioral Health
Thrives Priority Areas: Behavioral HealthCity of Chesapeake
55 vistas22 diapositivas
Examining Pleural Fluid.pptx por
Examining Pleural Fluid.pptxExamining Pleural Fluid.pptx
Examining Pleural Fluid.pptxFareeha Riaz
17 vistas18 diapositivas
General Anaesthesia por
General Anaesthesia General Anaesthesia
General Anaesthesia P.N.DESHMUKH
10 vistas8 diapositivas

Último(20)

Cholera Romy W. (3).pptx por rweth613
Cholera Romy W. (3).pptxCholera Romy W. (3).pptx
Cholera Romy W. (3).pptx
rweth61353 vistas
DEBATE IN CA BLADDER TMT VS CYSTECTOMY por Kanhu Charan
DEBATE IN CA BLADDER TMT VS CYSTECTOMYDEBATE IN CA BLADDER TMT VS CYSTECTOMY
DEBATE IN CA BLADDER TMT VS CYSTECTOMY
Kanhu Charan48 vistas
When HER2 Is Low or Negative: Emerging Evidence on Antibody-Drug Conjugates f... por PeerVoice
When HER2 Is Low or Negative: Emerging Evidence on Antibody-Drug Conjugates f...When HER2 Is Low or Negative: Emerging Evidence on Antibody-Drug Conjugates f...
When HER2 Is Low or Negative: Emerging Evidence on Antibody-Drug Conjugates f...
PeerVoice6 vistas
Examining Pleural Fluid.pptx por Fareeha Riaz
Examining Pleural Fluid.pptxExamining Pleural Fluid.pptx
Examining Pleural Fluid.pptx
Fareeha Riaz 17 vistas
Top Ayurvedic PCD Companies in India Riding the Wave of Wellness Trends por muskansbl01
Top Ayurvedic PCD Companies in India Riding the Wave of Wellness TrendsTop Ayurvedic PCD Companies in India Riding the Wave of Wellness Trends
Top Ayurvedic PCD Companies in India Riding the Wave of Wellness Trends
muskansbl0141 vistas
GAS CHROMATOGRAPHY-Principle, Instrumentation Advantage and disadvantage appl... por DipeshGamare
GAS CHROMATOGRAPHY-Principle, Instrumentation Advantage and disadvantage appl...GAS CHROMATOGRAPHY-Principle, Instrumentation Advantage and disadvantage appl...
GAS CHROMATOGRAPHY-Principle, Instrumentation Advantage and disadvantage appl...
DipeshGamare9 vistas
PATIENTCOUNSELLING in.pptx por skShashi1
PATIENTCOUNSELLING  in.pptxPATIENTCOUNSELLING  in.pptx
PATIENTCOUNSELLING in.pptx
skShashi121 vistas
Structural Racism and Public Health: How to Talk to Policymakers and Communit... por katiequigley33
Structural Racism and Public Health: How to Talk to Policymakers and Communit...Structural Racism and Public Health: How to Talk to Policymakers and Communit...
Structural Racism and Public Health: How to Talk to Policymakers and Communit...
katiequigley33912 vistas
AntiAnxiety Drugs .pptx por Dr Dhanik Mk
AntiAnxiety Drugs .pptxAntiAnxiety Drugs .pptx
AntiAnxiety Drugs .pptx
Dr Dhanik Mk21 vistas
Myocardial Infarction Nursing.pptx por Asraf Hussain
Myocardial Infarction Nursing.pptxMyocardial Infarction Nursing.pptx
Myocardial Infarction Nursing.pptx
Asraf Hussain13 vistas
Explore new Frontiers in Medicine with AI.pdf por Anne Marie
Explore new Frontiers in Medicine with AI.pdfExplore new Frontiers in Medicine with AI.pdf
Explore new Frontiers in Medicine with AI.pdf
Anne Marie11 vistas

Pulmonary Embolism- Diagnosis by Dr.Tinku Joseph

  • 1. PULMONARY EMBOLISM DIAGNOSIS Dr.Tinku Joseph DM Resident Dept. Of Pulmonary Medicine AIMS, Kochi.
  • 2. Diagnostic Tests  Imaging Studies – CXR – V/Q Scans – Spiral Chest CT – Pulmonary Angiography – Echocardiograpy  Laboratory Analysis – CBC, ESR, – D-Dimer – ABG’s  Ancillary Testing – ECG – Pulse Oximetry
  • 3. D-dimer Test  Fibrin split product  Circulating half-life of 4-6 hours  Quantitative test have 80-85% sensitivity, and 93-100% negative predictive value • False Positives: Pregnant Patients Post-partum < 1 week Malignancy Surgery within 1 week Advanced age > 80 years Sepsis Hemmorrhage CVA Collagen Vascular Diseases Hepatic Impairment Arch Intern Med 2004;140:589
  • 4. Diagnostic Testing • D-dimer – Qualitative • Bed side RBC agglutination test – “SimpliRED D-dimer” – Quantitative • Enzyme linked immunosorbent asssay “Dimertest” • Positive assay is > 500ng/ml • VIDAS D-dimer, 2nd generation ELISA test
  • 5. D-DIMER • False Positive D-Dimer – Pregnancy – Trauma – Postoperative Recovery – Inflammation – Cancer – Rheumatoid Factor – Older Age • False Negative D-Dimer – Heparin
  • 7. Prognostic Value of Troponins in Acute Pulmonary Embolism
  • 8.  Conclusion: Elevated troponin levels were associated with a high risk of (early) death resulting from pulmonary embolism (OR, 9.44; 95% CI, 4.14 to 21.49)  These findings identify troponin as a promising tool for rapid risk stratification of patients with pulmonary embolism.
  • 9. BNP & pro-BNP  Typically greater in patients with PE.  Sensitivity of 60% and specificity of 62%.  At a threshold of 500 pg/mL, the sensitivity of pro- BNP for predicting adverse events was 95%, and the specificity was 57%. Kucher N et al. Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation 2003 Apr 1; 107:1576-8.
  • 10. WBC  Poor sensitivity and nonspecific Can be as high as 20,000 in some patients Hb  PTE does not alter count but if extreme, consider polycythemia, a known risk factor ESR  Don’t get one, terrible test in regard to any predictive value
  • 11. Doppler ultrasound of leg veins Principle - Veins are normally compressible; Presence of DVT renders veins non-compressible 50% of patients with PE have positive ultrasound (95% of PE are due to leg DVT)
  • 12. ECG – 2 Most Common finding on ECG:  Nonspecific ST-segment and T-wave changes  Sinus Tachycardia – Historical abnormality suggestive of PE  S1Q3T3  Right ventricular strain  New incomplete RBBB
  • 13. Echocardiography  This modality generally has limited accuracy in the diagnosis.  The overall sensitivity and specificity for diagnosis of central and peripheral pulmonary embolism by ECHO is 59% and 77%.  It may allow diagnosis of other conditions that may be confused with pulmonary embolism.
  • 14. ECHO signs of PE  RV enlargement or hypokinesis especially free wall hypokinesis, with sparing of the apex (the McConnell sign)  60/60 Sign- Acceleration time of RV ejection <60ms in the presence of TR pressure gradient </= 60mmHg.  Interventricular septal flattening and paradoxical motion toward the LV resulting in a “D-shaped” LV in cross section.  Tricuspid regurgitation
  • 17. ABG analysis  ABG has a limited role.  It usually reveal hypoxemia, hypocapnia and respiratory alkalosis.  Alveolar arterial oxygen gradient , done at room air, a-a gradient > 15-20 is considered abnormal.
  • 18. Chest x ray  A normal or nearly normal chest x-ray
  • 19. Chest Xray  Chest radiograph findings in patient with pulmonary embolism Result Percent Cardiomegaly 27% Normal study 24% Atelectasis 23% Elevated Hemidiaphragm 20% Pulmonary Artery Enlargement 19% Pleural Effusion 18% Parenchymal Pulmonary Infiltrate 17% Am Heart J 1997;134:479-87
  • 20. Radiographic signs of acute pulmonary embolism  Signs with relative high specificity but low sensitivity for acute pulmonary embolism:  Decreased vascularity in the peripheral lung (Westermark sign).  Enlargement of the central pulmonary artery (Fleischner sign).  Enlarged right descending pulmonary artery (Palla's sign)  Pleural based areas of increased opacity (Hampton hump).  Hemidiaphragm elevation.
  • 21.  Non specific signs associated with acute pulmonary embolism that may be associated with other diseases:  Focal area of increased opacity.  Linear atelectasis.  Pleural effusion. Radiographic signs of acute pulmonary embolism
  • 23. Westermark sign, with hilar enlargement Dilatation of pulmonary vessels proximal to embolism along with collapse of distal vessels, often with a sharp cut off.
  • 26. Hampton’s hump  Dome shaped pleural based opacity due to lung infarction.  Pulmonary infarct is dome shaped instead of being wedge shaped because of double blood supply with preserved bronchial arteries resulting in sparing of the expected apex of the wedge.
  • 27. Radiographic Eponyms - Hampton’s Hump, Westermark’s Sign Westermark’s Sign Hampton’s Hump
  • 28. Ventilation/Perfusion Scan - “V/Q Scan”  A common modality to image the lung.  Relatively noninvasive.  In many centers remains the initial test of choice  Preferred test in pregnant patients  50 mrem vs 800mrem (with spiral CT)
  • 31. Ventilation/Perfusion Scan  HIGH PROBABILITY (>80%): 2 or more large mismatched segments or the equivalent.  any perfusion defect substantially larger than radiographic abnormality  INTERMEDIATE PROBABILITY (20-79%): 1 moderate to 2 large mismatched segments  LOW PROBABILITY (<20%): Non-segmental perfusion defects, matched defects  NORMAL: no perfusion defects
  • 32. PIOPED: PREDICTIVE VALUE V/Q SCAN SCAN CATEGORY CLINICAL SUSPICION 80-100% 20-79% 0-19% HIGH INTERMEDIATE LOW PIOPED INVESTIGATORS. JAMA.1990; 263: 2753-2759
  • 34. Spiral CT  Major advantage of Spiral CT is speed:  Often the patient can hold their breath for the entire study, reducing motion artifacts.  Allows for more optimal use of intravenous contrast enhancement.  Spiral CT is quicker than the equivalent conventional CT permitting the use of higher resolution acquisitions in the same study time.  Contraindicated in cases of renal disease.  Sensitive for PE in the proximal pulmonary arteries, but less so in the distal segments.
  • 35. CT Angiogram  Quickly becoming the test of choice for initial evaluation of a suspected PE.  CT unlikely to miss any lesion.  Better sensitivity, specificity and can be used directly to screen for PE.  Used to follow up “non diagnostic V/Q scans.
  • 36. CT Angiogram Chest computed tomography scanning demonstrating extensive embolization of the pulmonary arteries.
  • 37. Multidetector Helical CT Pulmonary Angiography
  • 38. Multidetector Helical CT Pulmonary Angiography Advantages
  • 39. Multidetector Helical CT Pulmonary Angiography Limitations
  • 40. CT findings of acute pulmonary embolism Vascular abnormalities:  Intraluminal filling defects that forms an acute angle with the vessel wall & may be surrounded by contrast material (polo mint sign or railway sign).  Total cutoff of vascular enhancement.  Enlargement of the occluded vessel. Ancillary findings:  Pleural based wedge shaped areas of increased attenuation with no contrast enhancement.  Linear atelectasis.
  • 41. Partial eccentric filling defect with acute angle with the vessel wall
  • 44. Enlargment of the occluded vessel
  • 45. Ancillary findings of acute pulmonary embolism (atelectatic band)
  • 46. MRA
  • 47. MRA
  • 48. Pulmonary angiogram  Gold Standard.  Positive angiogram provides 100% certainty that an obstruction exists in the pulmonary artery.  Negative angiogram provides > 90% certainty in the exclusion of PE.  “Court of Last Resort”
  • 49. Pulmonary angiogram Left-sided pulmonary angiogram showing extensive filling defects within the left pulmonary artery and its branches.
  • 50. Angiographic severity scoring Miller, et al. Amer Journ Roent,Rad Therapy & Nuc Med. 125(4):895-9, 1975 Dec.
  • 51. Further Alternative Imaging Tests (Newer modalities) Dual-energy CTPA Electrocardiographically gated CTPA Three-dimensional images acquired by single- photon emission computed tomography (SPECT) using a gamma-emitting radioisotope may improve V/Q scintigraphy and has a lower radiation dose.
  • 52. Dual-energy CTPA Provides functional and anatomic lung imaging Demonstrates perfusion defects beyond obstructive and non- obstructive clots Diagnostic accuracy requires further research Advantages Indirect evaluation of peripheral pulmonary arterial bed Disadvantages Longer data acquisition time Increased radiation exposure
  • 53. Dual-energy CTPA [A] Axial reconstruction with color-coded dual energy perfusion information. Note the large perfusion defects in both lungs. [B] Coronal reconstruction. Only the apical parts show a normal perfusion.
  • 54. Electrocardiographically gated CTPA Can differentiate between cardiac events and PE  May be of use in patients presenting with thoracic pain and suspected PE, cardiac events, or aorta dissection.  More contrast material is needed, and the radiation dose is higher compared with CTPA.
  • 55. Imaging in Pregnancy  No validated clinical decision rules  No consensus in evidence for diagnostic imaging algorithm  Balance risk of radiation vs. risk of missed fatal diagnosis or unnecessary anticoagulation  MDCT delivers higher radiation dose to mother but lower dose to fetus than V/Q scanning  Consider low-dose CT-PA or reduced-dose lung scintigraphy Stein P et al. Radiology. 2007 Jan;242:15-21. Marik PE; Plante LA. N. Engl. J. Med. 2008;359:2025-33.
  • 56. Imaging-nut shell  Plain chest radiograph – Usually normal and non- specific signs.  Radionuclide ventilation-perfusion lung scan – Excellent negative predictive value.  CT Angiography of the pulmonary arteries – Quickly becoming method of choice.  Pulmonary angiography – Gold standard but invasive.
  • 57. Diagnostic Tests for Suspected Pulmonary Embolism Oxygen saturation Nonspecific, but suspect PE if there is a sudden, otherwise unexplained decrement D-dimer An excellent “rule-out” test if normal, especially if accompanied by non–high clinical probability Electrocardiography May suggest an alternative diagnosis, such as myocardial infarction or pericarditis Lung scanning Usually provides ambiguous result; used in lieu of chest CT for patients with anaphylaxis to contrast agent, renal insufficiency, or pregnancy Chest CT The most accurate diagnostic imaging test for PE ; beware if CT result and clinical likelihood probability are discordant Pulmonary angiography Invasive, costly, uncomfortable; used primarily when local catheter intervention is planned Echocardiography Best used as a prognostic test in patients with established PE rather than as a diagnostic test ; many patients with large PE will have normal echocardiograms Venous ultrasonography Excellent for diagnosis of acute symptomatic proximal DVT; a normal study does not rule out PE because a recent leg DVT may have embolized completely; calf vein imaging is operator dependent Magnetic resonance Reliable only for imaging of proximal segmental pulmonary arteries; requires gadolinium but does not require iodinated contrast agent
  • 60. Pulmonary Embolism (Treatment) Part 2 Dr.Tinku Joseph DM Resident Dept. Of Pulmonary Medicine AIMS, Kochi.
  • 61. Approach to the patient of PE  Stratify patients into high clinical likelihood or non– high clinical likelihood of PE .  In low-risk group, only about 5% of patients were subsequently diagnosed with PE.
  • 62. How do we work up? - Pretest Probability  Definition: “The probability of the target disorder (PE) before a diagnostic test result is known”.  Used to decide how to proceed with diagnostic testing and final disposition
  • 63. Classic Wells Criteria to Assess Clinical Likelihood of Pulmonary Embolism SCORE POINTS DVT symptoms or signs 3 An alternative diagnosis is less likely than PE 3 Heart rate >100/min 1.5 Immobilization or surgery within 4 weeks 1.5 Prior DVT or PE 1.5 Hemoptysis 1 Cancer treated within 6 months or metastatic 1 >4 score points = high probability ≤4 score points = non–high probability JAMA 295:172,2006
  • 64. Simplified Wells Criteria to Assess Clinical Likelihood of Pulmonary Embolism DVT symptoms or signs 1 An alternative diagnosis is less likely than PE 1 Heart rate >100/min 1 Immobilization or surgery within 4 weeks 1 Prior DVT or PE 1 Hemoptysis 1 Cancer treated within 6 months or metastatic 1 >1 score point = high probability ≤1 score point = non–high probability Thromb Haemost 101:197,2009
  • 67. ACC/AHA Classification • Massive • Submassive • Low-Risk PE • Pulmonary infarction syndrome
  • 68. Massive PE • Acute PE with sustained hypotension (systolic blood pressure 90 mm Hg for at least 15 minutes or requiring inotropic support, not due to a cause other than PE, such as  Arrhythmia  Hypovolemia  Sepsis  Left ventricular (LV) dysfunction  Pulselessness  Persistent profound bradycardia (heart rate 40 bpm with signs or symptoms of shock)
  • 69. Submassive PE • Acute PE without systemic hypotension (systolic blood pressure 90mm Hg) but with either RV dysfunction or myocardial necrosis • RV dysfunction means the presence of at least 1 of the following  RV dilation (apical 4-chamber RV diameter divided by LV diameter 0.9) or RV systolic dysfunction on echocardiography  RV dilation (4-chamber RV diameter divided by LV diameter 0.9) on CT  Elevation of BNP (90 pg/mL)  Elevation of N-terminal pro-BNP (500 pg/mL)  Electrocardiographic changes (new complete or incomplete right bundle- branch block, anteroseptal ST elevation or depression, or anteroseptal T- wave inversion) Torbicki A et al. Eur Heart J 29(18):2276–2315, 2008
  • 70. Low-Risk PE • Acute PE and the absence of the clinical markers of adverse prognosis that define massive or submassive PE
  • 71. Pulmonary Infarction Syndrome • Caused by a tiny peripheral pulmonary embolism  Pleuritic chest pain, often not responsive to narcotics  Low-grade fever  Leukocytosis  Pleural rub  Occasional scant hemoptysis
  • 72. Treatment: Goals:  Prevent death from a current embolic event  Reduce the likelihood of recurrent embolic events  Minimize the long-term morbidity of the event
  • 73. Treatment options  Symptomatic treatment: – ABCD approach – Oxygen – Analgesia  Anticoagulation: – IV Heparin – S/C LMWH eg Enoxaparine, Dalteparine – Oral Warfarin  IVC filter: If there is contra-indications for anti-coagulation  Thrombolysis: tPA eg Alteplase, Tenectaplase  Surgical procedures: Pulmonary embolectomy
  • 74. Treatment options  Massive PE: Thrombolysis/embolectomy  Sub-massive PE: Strongly consider thrombolysis/embolectomy but need to balance risk of bleeding  Non-massive PE: Anticoagulation
  • 75. KEY STUDIES & guidelines IN PE TREATMENT • 1937 Murry: first use of heparin • 1960 Barritt:“RCT” warfarin vs. placebo • 1968 Sasahara: UPET • 2003 Konstantinides: Alteplase
  • 77. Prevention  ACCP guide lines • For acutely ill hospitalised medical pts at low risk of thrombosis ACCP recommends against the use of prophylaxsis. • Pts at moderate to high risk but who are not bleeding or at high risk of bleeding should be given either LMWH or UFH or fondaparinux.
  • 79. Prevention of PE 1 Hospitalization with medical illness Enoxaparin 40 mg SC qd or Dalteparin 5000 units SC qd or Fondaparinux 2.5 mg SC qd (in patients with a heparin allergy such as heparin-induced thrombocytopenia) or Graduated compression stockings or intermittent pneumatic compression 2 General surgery Unfractionated heparin 5000 units SC bid or tid or Enoxaparin 40 mg SC qd or Dalteparin 2500 or 5000 units SC qd 3 Major orthopedic surgery Warfarin (target INR 2 to 3) or Enoxaparin 30 mg SC bid or Enoxaparin 40 mg SC qd or Dalteparin 2500 or 5000 units SC qd or Fondaparinux 2.5 mg SC qd Rivaroxaban 10 mg qd (in Canada and Europe) Dabigatran 220 mg bid (in Canada and Europe)
  • 80. 4 Oncologic surgery Enoxaparin 40 mg SC qd 5 Neurosurgery Unfractionated heparin 5000 units SC bid or Enoxaparin 40 mg SC qd and Graduated compression stockings or intermittent pneumatic compression Consider surveillance lower extremity ultrasonography 6 Thoracic surgery Unfractionated heparin 5000 units SC tid and Graduated compression stockings or intermittent pneumatic compression Prevention of PE
  • 81. • For pts who are bleeding or at risk of bleeding use leg compression devices only. • Pts are considered to be at high risk of bleeding if they meet any of the following criteria • Active gastrodeodenal ulcer • Bleeding in 3 months prior to admission • Platelet count <50,000 Prevention of PE
  • 82.  Or if they had multiple risk factors for bleeding of lesser predictive strengthlike age >84 yrs,severe renal failure , hepatic failure with INR > 1.5 , male ,current cancer, ICU admission. Prevention of PE
  • 83. References  Harrison -18 th edition  ACCP guidelines  Fishman's Pulmonary Diseases and Disorders  Crofton and Douglas's Respiratory Diseases (Wiley, 2000)